眾生藥業(002317.SZ):控股子公司逸舒製藥獲批在新三板終止掛牌
格隆匯3月31日丨眾生藥業(002317.SZ)公佈,近日,公司控股子公司逸舒製藥收到全國中小企業股份轉讓系統有限責任公司出具的《關於同意廣東逸舒製藥股份有限公司股票終止在全國中小企業股份轉讓系統掛牌的函》(股轉系統函【2020】706號),同意逸舒製藥股票(證券代碼:832796,證券簡稱:逸舒製藥)自2020年4月2日起終止在全國中小企業股份轉讓系統掛牌。
此次逸舒製藥終止掛牌事項,不會對其日常經營造成不利影響。該事項不會影響公司的正常業務開展,也不會對公司的生產經營產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.